The Business Times
business-time-50

Medtech startup set to revolutionise cancer diagnostics

google-preferred-sourceAdd BT as a preferred source
Published Wed, Jan 21, 2015 · 09:50 PM

    Singapore

    A SINGAPORE-based medtech startup that is looking to bring low-cost, simple-to-use cancer diagnostics tests to the masses, is set to revolutionise the global cancer diagnostics market that is projected to hit some US$168.6 billion in 2020.

    VolitionRx has developed a blood-based - therefore non-invasive - test platform that can potentially diagnose a wide range of cancers including colorectal and prostate, two of the most common cancers affecting men and women globally, The Business Times has learnt.

    Startups

    TRENDING NOW

    Koh Boon Hwee says humans have accepted that robots can take over the most repetitive, manual tasks, but are nervous about AI, which can also think.

    With AI, it’s not about coding better; workers need to think better: Koh Boon Hwee

    Recent cuts at e-commerce platforms such as Shopee is signalling shifting business priorities.

    E-commerce job cuts signal S-E Asia’s shift from scaling to deeper user engagement

    In hiring for AI-fluent users, companies will do well to better define and test applicants on their capacity for human oversight.

    Employers want AI-fluent employees. Hiring them is the challenge

    Philippine’s Maharlika support for Petron through a credit facility shows the sovereign fund’s role in the nation’s energy security.

    Early payout from Philippines’ Maharlika Investment Fund raises eyebrows over its true nature

    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More